Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Wayfair Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.42 (market cap $29.60B), while Wayfair Inc trades at $103.54 (market cap $14.14B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.1× Wayfair Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | W | |
|---|---|---|
Market Cap | $29.60B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $119.05 |
52-Week Low | $205.48 | $57.40 |
Enterprise Value | $27.56B | $16.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Wayfair (W) trades at $103.59, up 0.25% with bullish technical signals including a golden cross pattern. The company reported strong Q2 2026 results with EPS of $0.95 beating estimates and 7.5% revenue growth. Despite negative net margins, operating cash flow improved to $534 million in 2025. Analyst consensus leans bullish with 52% buy ratings and a $122 price target representing 18% upside potential.
The outlook remains positive driven by U.S. market share gains and margin expansion guidance, though risks include persistent losses and high debt levels. Technical support at $102 provides near-term protection while resistance at $105-108 marks the next challenge. The stock's momentum appears sustainable if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
